Provided by Tiger Trade Technology Pte. Ltd.

Seer, Inc.

1.79
+0.04002.29%
Post-market: 1.790.00000.00%18:25 EST
Volume:87.61K
Turnover:157.19K
Market Cap:100.69M
PE:-1.31
High:1.81
Open:1.78
Low:1.78
Close:1.75
52wk High:2.41
52wk Low:1.62
Shares:56.25M
Float Shares:39.55M
Volume Ratio:0.39
T/O Rate:0.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3630
EPS(LYR):-1.3890
ROE:-25.74%
ROA:-15.19%
PB:0.37
PE(LYR):-1.29

Loading ...

Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

GlobeNewswire
·
Feb 06

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

prnewswire
·
Dec 08, 2025

Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

GlobeNewswire
·
Dec 01, 2025

Seer, Inc. Earnings Call: Achievements Amid Challenges

TIPRANKS
·
Nov 08, 2025

Seer Inc. Showcases Deep Proteomics Advances at HUPO World Congress

Reuters
·
Nov 07, 2025

Life sciences company Seer's Q3 net loss narrows

Reuters
·
Nov 07, 2025

Seer Q3 EPS USD -0.32

Reuters
·
Nov 07, 2025

Seer Q3 EPS $(0.32) Misses $(0.31) Estimate, Sales $4.121M Beat $4.000M Estimate

Benzinga
·
Nov 07, 2025

Seer Inc. reports Q3 revenue of $4.1 million

Reuters
·
Nov 07, 2025

Seer Reports Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 07, 2025

Seer Inc expected to post a loss of 30 cents a share - Earnings Preview

Reuters
·
Nov 05, 2025

Seer Inc. to Participate in UBS Global Healthcare Conference

Reuters
·
Oct 30, 2025

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire
·
Oct 17, 2025

RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases

Reuters
·
Oct 16, 2025

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

GlobeNewswire
·
Oct 14, 2025

Seer Inc announces date for special stockholder meeting

Reuters
·
Oct 10, 2025

Seer Inc to Showcase Proteomics Advances at American Society of Human Genetics Annual Meeting

Reuters
·
Oct 10, 2025

Asia cohort of Phase 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) achieved statistically significant and clinically meaningful improvement in overall survival versus osimertinib in EGFR-mutated non-small cell lung cancer

prnewswire
·
Sep 12, 2025

Seer Inc. Appoints Isaac Ro to Board of Directors, Enhancing Leadership with Financial and Life Sciences Expertise

Reuters
·
Sep 06, 2025

Seer Inc. Files Initial Statement of Beneficial Ownership; Isaac Ro Named as Director

Reuters
·
Sep 04, 2025